Alexion Pharmaceuticals
2021AstraZeneca acquired Alexion to enter the rare disease market with a proven complement-biology platform, gaining Soliris and Ultomiris as immediate blockbuster revenue drivers and establishing a dedicated rare disease unit headquartered in Boston. The acquisition provided scientific expertise in immunology that AstraZeneca lacked internally, along with specialized commercial infrastructure for ultra-rare disease diagnosis and patient identification. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
MedImmune
2007AstraZeneca acquired MedImmune to gain biologics manufacturing capabilities, antibody technology platforms, and the Synagis respiratory syncytial virus franchise. The deal represented AstraZeneca's recognition that the future of pharmaceutical innovation lay in large-molecule biologics rather than small-molecule chemistry alone. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
Cambridge Antibody Technology
2006AstraZeneca acquired Cambridge Antibody Technology for $892 million to secure antibody discovery and humanization technologies that would accelerate the company's transition from small molecules to biologics. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
Almirall Respiratory Portfolio
2014AstraZeneca acquired the respiratory portfolio of Spanish pharmaceutical company Almirall, including Eklira and rights to a pipeline of COPD and asthma candidates, to strengthen its position in the respiratory market ahead of Symbicort's patent expiration. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
Fusion Pharmaceuticals
2024AstraZeneca acquired Fusion Pharmaceuticals for $2 billion in cash to access radiopharmaceutical and antibody-drug conjugate technologies, particularly the targeted alpha therapies platform that delivers potent radioisotopes directly to cancer cells. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
Gracell Biotechnologies
2024AstraZeneca acquired Gracell Biotechnologies for $1.2 billion to access autologous cell therapy manufacturing capabilities and the FasTCAR platform, which reduces CAR-T production time from weeks to days. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
CinCor Pharma
2023AstraZeneca acquired CinCor Pharma for $1.1 billion to access baxdrostat, a selective aldosterone synthase inhibitor for resistant hypertension and primary aldosteronism, expanding the cardiovascular pipeline beyond SGLT2 inhibitors. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
EsoBiotec
2025AstraZeneca acquired Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology that delivers CAR-T genetic modifications directly within the patient's body, eliminating the need for ex vivo manufacturing. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.